FY2024 Earnings Forecast for Masimo Issued By Zacks Research

Masimo Co. (NASDAQ:MASI) – Investment analysts at Zacks Research boosted their FY2024 earnings per share estimates for Masimo in a research report issued to clients and investors on Tuesday, November 26th. Zacks Research analyst I. Bandyopadhyay now forecasts that the medical equipment provider will post earnings per share of $4.00 for the year, up from their prior forecast of $3.84. The consensus estimate for Masimo’s current full-year earnings is $4.04 per share. Zacks Research also issued estimates for Masimo’s Q4 2024 earnings at $1.39 EPS, Q1 2025 earnings at $0.89 EPS, Q2 2025 earnings at $0.99 EPS, Q4 2025 earnings at $1.25 EPS, FY2025 earnings at $4.20 EPS and FY2026 earnings at $4.84 EPS.

Masimo (NASDAQ:MASI) last released its earnings results on Tuesday, November 5th. The medical equipment provider reported $0.98 earnings per share (EPS) for the quarter, beating analysts’ consensus estimates of $0.84 by $0.14. The business had revenue of $504.60 million for the quarter, compared to analyst estimates of $502.87 million. Masimo had a return on equity of 14.98% and a net margin of 3.85%. The company’s revenue for the quarter was up 5.4% compared to the same quarter last year. During the same quarter in the previous year, the company posted $0.63 earnings per share.

Other equities research analysts also recently issued research reports about the company. BTIG Research upped their price target on Masimo from $166.00 to $170.00 and gave the stock a “buy” rating in a report on Monday, October 14th. Wells Fargo & Company increased their target price on shares of Masimo from $160.00 to $171.00 and gave the company an “overweight” rating in a report on Wednesday, November 6th. Piper Sandler boosted their price target on shares of Masimo from $165.00 to $180.00 and gave the stock an “overweight” rating in a report on Wednesday, November 6th. Stifel Nicolaus reiterated a “buy” rating and issued a $190.00 price objective (up previously from $170.00) on shares of Masimo in a research note on Friday, November 22nd. Finally, Raymond James upgraded Masimo from a “market perform” rating to an “outperform” rating and set a $170.00 target price on the stock in a research note on Wednesday, November 6th. Three research analysts have rated the stock with a hold rating and five have issued a buy rating to the company’s stock. According to MarketBeat.com, Masimo currently has a consensus rating of “Moderate Buy” and a consensus price target of $167.00.

Masimo Price Performance

Shares of NASDAQ MASI opened at $170.89 on Wednesday. The company has a debt-to-equity ratio of 0.50, a quick ratio of 1.11 and a current ratio of 2.01. The firm’s 50-day simple moving average is $147.03 and its 200 day simple moving average is $129.03. The stock has a market cap of $9.15 billion, a price-to-earnings ratio of 117.86 and a beta of 0.97. Masimo has a fifty-two week low of $91.60 and a fifty-two week high of $178.27.

Hedge Funds Weigh In On Masimo

Several institutional investors have recently bought and sold shares of MASI. NBC Securities Inc. lifted its position in shares of Masimo by 47.1% during the 3rd quarter. NBC Securities Inc. now owns 228 shares of the medical equipment provider’s stock valued at $30,000 after buying an additional 73 shares during the last quarter. GAMMA Investing LLC raised its position in shares of Masimo by 75.0% in the second quarter. GAMMA Investing LLC now owns 259 shares of the medical equipment provider’s stock valued at $33,000 after purchasing an additional 111 shares during the period. Northwestern Mutual Wealth Management Co. boosted its holdings in Masimo by 133.3% in the 2nd quarter. Northwestern Mutual Wealth Management Co. now owns 350 shares of the medical equipment provider’s stock worth $44,000 after buying an additional 200 shares during the period. Lazard Asset Management LLC grew its stake in Masimo by 5,730.0% in the 1st quarter. Lazard Asset Management LLC now owns 583 shares of the medical equipment provider’s stock valued at $85,000 after buying an additional 573 shares in the last quarter. Finally, HHM Wealth Advisors LLC lifted its position in shares of Masimo by 25.0% during the second quarter. HHM Wealth Advisors LLC now owns 625 shares of the medical equipment provider’s stock worth $79,000 after acquiring an additional 125 shares in the last quarter. Hedge funds and other institutional investors own 85.96% of the company’s stock.

Masimo Company Profile

Masimo Corporation develops, manufactures, and markets various patient monitoring technologies, and automation and connectivity solutions worldwide. The company offers masimo signal extraction technology (SET) pulse oximetry with measure-through motion and low perfusion pulse oximetry monitoring to address the primary limitations of conventional pulse oximetry; Masimo rainbow SET platform, including rainbow SET Pulse CO-Oximetry products that allows noninvasive monitoring of carboxyhemoglobin, methemoglobin, hemoglobin concentration, fractional arterial oxygen saturation, oxygen content, pleth variability index, rainbow pleth variability index, respiration rate from the pleth, and oxygen reserve index, as well as acoustic respiration monitoring, SedLine brain function monitoring, NomoLine capnography and gas monitoring, and regional oximetry.